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Increased Persistence of Initial Treatment for HIV
Infection With Modern Antiretroviral Therapy
Thibaut Davy-Mendez, MSPH, Joseph J. Eron, MD, Oksana Zakharova, MS,
David A. Wohl, MD, and Sonia Napravnik, PhD
Background: Initiating antiretroviral therapy (ART) early improves
clinical outcomes and prevents transmission. Guidelines for first-line
therapy have changed with the availability of newer ART agents. In
this study, we compared persistence and virologic responses with
initial ART according to the class of anchor agent used.
Setting: An observational clinical cohort study in the Southeastern
United States.
Methods: All HIV-infected patients participating in the UNC
Center for AIDS Research Clinical Cohort (UCHCC) and initiating
ART between 1996 and 2014 were included. Separate time-to-event
analyses with regimen discontinuation and virologic failure as
outcomes were used, including Kaplan–Meier survival curves and
adjusted Cox proportional hazards models.
Results: One thousand six hundred twenty-four patients were
included (median age of 37 years at baseline, 28% women, 60%
African American, and 28% white). Eleven percent initiated
integrase strand transfer inhibitor (INSTI), 33% non–nucleoside
reverse transcriptase inhibitor (NNRTI), 20% boosted protease
inhibitor, 27% other, and 9% NRTI only regimens. Compared with
NNRTI-containing regimens, INSTI-containing regimens had an
adjusted hazard ratio of 0.49 (95% confidence interval, 0.35 to 0.69)
for discontinuation and 0.70 (95% confidence interval, 0.46 to 1.06)
for virologic failure. All other regimen types were associated with
increased rates of discontinuation and failure compared with NNRTI.
Conclusions: Initiating ART with an INSTI-containing regimen
was associated with lower rates of regimen discontinuation and
virologic failure.
Key Words: HIV, antiretroviral therapy, integrase inhibitors, pro-
spective studies, United States
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INTRODUCTION
Initiating antiretroviral therapy (ART) early in HIV
infection improves clinical outcomes and prevents trans-
mission.1,2 US treatment guidelines have changed with the
availability of newer ART agents and currently recommend
starting ART with a combination of 2 NRTIs, and an
integrase strand transfer inhibitor (INSTI), or a boosted
protease inhibitor (bPI).3 The effectiveness of INSTI-
containing regimens compared with previously available
regimens has not been well characterized. In this study, we
compared response to initial ART in the clinical setting
including continuation of the initial regimen, known as
persistence or durability, and virologic response.
METHODS
All patients initiating ART in the University of North
Carolina (UNC) Center for AIDS Research HIV Clinical
Cohort, 1996–2014, were included. This prospective cohort
of all primary HIV care patients at the UNC Hospitals is
representative of HIV-infected patients in care in North
Carolina.4 Patients were followed from the first ART
initiation (baseline) until the first of outcome, loss to
follow-up, death, or November 2015. The 2 primary out-
comes evaluated were ART discontinuation, defined as
change in anchor agent class or stopping ART for longer
than 2 weeks, and virologic failure, defined as the first HIV
RNA level $400 copies/mL after 24 weeks of therapy in an
intention-to-treat approach, where patients lost to follow-up
with HIV RNA ,400 copies/mL were censored and changes
in therapy were ignored. ART regimen categories were based
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(n = 150) P*
Baseline characteristics
Age y, median (IQR) 37 (29 to 46) 38 (26 to 48) 37 (29 to 46) 37 (29 to 47) 37 (29 to 45) 37 (31 to 45) 0.90
Women, No (%) 460 (28%) 30 (17%) 124 (23%) 107 (32%) 146 (34%) 53 (35%) ,0.001
Race†, No (%) 0.003
African American 979 (60%) 109 (63%) 328 (61%) 174 (53%) 268 (62%) 100 (67%)
White 453 (28%) 52 (30%) 129 (24%) 112 (34%) 122 (28%) 38 (25%)
Other 192 (12%) 12 (7%) 79 (15%) 45 (14%) 44 (10%) 12 (8%)
CD4 cell count cells/mm3,
median (IQR)
277 (104 to 463) 403 (246 to 579) 279 (116 to 468) 230 (78 to 401) 237 (69 to 442) 341 (127 to 475) ,0.001
HIV RNA level log10
copies/mL, median
(IQR)
4.8 (4.2 to 5.3) 4.4 (3.9 to 5.0) 4.8 (4.2 to 5.4) 4.9 (4.3 to 5.5) 4.9 (4.2 to 5.4) 4.6 (3.9 to 5.1) ,0.001
Calendar yr, median
(IQR)
2005 (2000 to 2010) 2013 (2012 to 2014) 2007 (2002 to 2010) 2007 (2005 to 2010) 1999 (1998 to 2003) 1998 (1997 to 2001) ,0.001
Follow-up yrs, median
(IQR)‡
5.5 (2.7 to 9.7) 2.3 (1.5 to 3.1) 5.5 (3.2 to 8.8) 5.5 (3.0 to 8.7) 6.6 (3.2 to 14.2) 9.7 (2.7 to 14.7) ,0.001
Lost to follow-up,
No (%)




0.48 (0.35 to 0.67) 1 (reference) 1.23 (1.04 to 1.46) 1.59 (1.37 to 1.85) 3.02 (2.48 to 3.68) NA
Adjusted HR single
model (95% CI)k




0.56 (0.40 to 0.80) 1 (reference) 1.28 (1.08 to 1.52) 1.58 (1.35 to 1.85) 2.61 (1.98 to 3.43) NA
Adjusted HR separate
models (95% CI)k
0.52 (0.34 to 0.80) 1 (reference) 1.28 (1.07 to 1.53) 1.39 (1.16 to 1.67) 2.76 (2.00 to 3.82) NA
Time to virologic failure
Unadjusted HR single
model (95% CI)k
0.46 (0.31 to 0.67) 1 (reference) 1.13 (0.92 to 1.38) 1.91 (1.61 to 2.27) 3.06 (2.46 to 3.81) NA
Adjusted HR single
model (95% CI)k




0.74 (0.48 to 1.13) 1 (reference) 1.20 (0.97 to 1.47) 1.86 (1.55 to 2.23) 1.49 (1.10 to 2.01) NA
Adjusted HR separate
models (95% CI)k
0.59 (0.34 to 1.03) 1 (reference) 1.25 (1.01 to 1.55) 1.28 (1.04 to 1.57) 1.39 (1.00 to 1.94) NA
*P values from x2 and Kruskal–Wallis tests.
†Race for this study was based on medical record reviews and categorized by the investigators. We assessed race in this study given previous evidence of an association with HIV
clinical outcomes.
‡Follow-up years defined as time from ART initiation until the first of death, loss to follow-up (last clinic visit plus 12 months), or administrative censoring (November 2015).
§Reasons for discontinuation included virologic failure and stopping ART for more than 2 weeks (23% and 37%, respectively) overall and for INSTI (5% and 54%), NNRTI (18%
and 42%), bPI (20% and 35%), other (29% and 35%), and NRTI (29% and 26%).
║Estimates from Cox proportional hazards models. Single model estimates based on 1 model including all patients initiating INSTI (raltegravir 53, dolutegravir 12, and elvitegravir
108); NNRTI (efavirenz 499 and rilpivirine 37); bPI (lopinavir 160, atazanavir 98, and darunavir 73); other (434); and NRTI (150). Separate model estimates based on fitting 4 separate
models for patients initiating (1) INSTI and NNRTI between 2007 and 2014 (raltegravir 53, dolutegravir 12, elvitegravir 108, efavirenz 240, and rilpivirine 37); (2) bPI and NNRTI
between 2000 and 2014 (lopinavir 154, atazanavir 98, darunavir 73, efavirenz 467, and rilpivirine 37); (3) other and NNRTI between 1998 and 2014 (other 359, efavirenz 499, and
rilpivirine 37); and (4) NRTI and NNRTI between 1998 and 2005 (NRTI 83 and efavirenz 221). Adjusted models included age, sex, race, CD4 cell count, HIV RNA level, and calendar
year, all measured at ART initiation.
IQR, interquartile range; NA, not applicable.
on anchor agent: INSTI (any INSTI), bPI (ritonavir-boosted 
atazanavir, darunavir, or lopinavir), non–nucleoside reverse 
transcriptase inhibitor (NNRTI, efavirenz, or rilpivirine), 
other (including unboosted and other bPI), and NRTI (regi-
mens including only NRTIs). Patients provided written 
informed consent to participate in the clinical cohort, and the 
UNC Institutional Review Board approved both the cohort 
study and this secondary data analysis.
Separate time-to-event analyses were performed for 
each outcome of interest, including Kaplan–Meier survival 
curves and Cox proportional hazards models adjusted for 
baseline age, sex, race, CD4 cell count, HIV RNA level, and 
calendar year. We excluded patients missing baseline CD4 or 
HIV RNA measurements. In a sensitivity analysis, we 
included patients missing baseline measurements and used 
multiple imputations with Markov Chain Monte Carlo and 50
imputations based on age, sex, race, men who have sex with
men status, injection drug use, year of ART initiation, and
ART regimen. We included the calendar year using disjoint
indicator variables for the periods 1996–2000, 2001–2005,
2006–2010, and 2011–2014. Because ART agent availability
changed over time, we also fit separate models for INSTI,
bPI, other, and NRTI, each in comparison with NNRTI, re-
stricting to calendar years where both ART regimen types
were available, including calendar years as a continuous vari-
able. To account for shorter follow-up of INSTI-initiating
patients, we also conducted sensitivity analyses, where we
restricted follow-up time for all patients to 3 years after ART
initiation. For all estimates, 95% confidence intervals (95% CIs)
were calculated and P values were 2 sided; P values ,0.05
were considered statistically significant. Analyses were per-
formed in SAS software, version 9.4 (SAS Institute, Cary, NC).
RESULTS
A total of 1624 patients who initiated ART between
1996 and 2014 were 28% women, 60% African American,
28% white, and a median of 37 years old at baseline (Table
1). Eleven percent initiated INSTI, 33% NNRTI, 20% bPI,
27% other, and 9% NRTI only regimens. The most common
NRTI backbone combinations were emtricitabine/tenofovir
disoproxil fumarate (FTC/TDF) among patients on INSTI
(92%); FTC/TDF and zidovudine/lamivudine (3TC) among
patients on NNRTI (59% and 22%, respectively); and TDF/
FTC, zidovudine/3TC, and abacavir/3TC among patients on
bPI (57%, 18%, and 9%, respectively). Patients initiating
different ART regimens differed significantly on most
baseline characteristics including sex, race, and year of
starting ART. Notably, CD4 cell counts were statistically
significantly different by ART regimen with a median of 403,
FIGURE 1. Primary endpoints. Shown are unadjusted Kaplan–Meier estimates of time to discontinuation of first ART (A), time to
virologic failure of initial ART (B), and by ART regimen type. C and D show unadjusted Kaplan–Meier estimates of time to
discontinuation and time to virologic failure, respectively, restricting to patients initiating INSTI and NNRTI regimens 2007 and
later.
The greater INSTI regimen persistence likely captures
the contributions of favorable safety, efficacy, and tolera-
bility profiles of INSTI regimens. Randomized clinical trials
of INSTI agents have reported rare drug discontinuations
because of adverse events, which were generally mild or
moderate and lower than for NNRTI-based regimens and
high virologic response rates and low failure rates that were
comparable or better than NNRTI.10–12 Our findings of
INSTI effectiveness from routine clinical care therefore
extend these previous results and suggest that more
tolerable regimens with high efficacy result in increased
initial ART persistence in a real-world setting and with
longer observation.
Our findings are limited by smaller sample size and
person-time available for INSTI initiators and possible
residual confounding because of differences in baseline
clinical covariates. In addition, specific reasons for discon-
tinuation were not examined and may have varied across
initial ART regimens. This study was also conducted at
a single clinical site and, therefore, the generalizability of our
results should be considered carefully. The demographic
make-up of our clinical site is, however, very similar to the
demographics of the HIV epidemic in Southeastern United
States.4 Expanding these analyses to national and interna-
tional cohort collaborations and including future years of
INSTI clinical care experience will be important to confirm
these initial findings and inform clinical care practice.
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